| Why carry out this study? |
| A network meta-analysis was performed, evaluating approved first-line tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). |
| This provided an up-to-date, comprehensive analysis of phase II/III randomized controlled trial data. |
| What was learned from this study? |
| No significant efficacy differences between approved first-line TKIs were observed. |
| Tivozanib ranked the most favourable in the analysis of grade 3 and 4 adverse events. |
| This produced indirect evidence to support clinical decisions and planning of future trials. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.